VETOQUINOL MOBILITY PROGRAM CLINICAL STUDY GRANT

PROPOSAL GUIDELINES

The Panel invites submission of proposals with the following guidelines:

Grant proposals will be written in English using Microsoft Word (.doc or .docx) or rich text format (.rtf), use a font size of 10 - 12, and limited to 10 pages (excluding title page, references, budget and timeline). Proposals should include the following:

TITLE

The first page of the submission should include a brief, descriptive title and the name, credentials, and contact information of the principal investigator and names, credentials, and level of involvement of co-investigators. This page will be separated from the remainder of the submission to avoid investigator or affiliation influence on the selection panel. The title (or an abbreviated title) without investigator/affiliation information should be included in the header of subsequent pages.

ABSTRACT

A short abstract of no more than 250 words highlighting the objectives, design, and outcome variables.

OBJECTIVE

A statement of what will be shown, the hypothesis and specific aims to be tested, and the endpoints measured.

BACKGROUND AND CLINICAL SIGNIFICANCE

A brief narrative describing the importance of the study and its relevance to the clinical management of osteoarthritis. This should include a review of the available literature and clearly identify the knowledge gap. Preliminary data is not required but is very helpful in assessment of feasibility.

EXPERIMENTAL DESIGN

A description of the methods (selection criteria, inclusion criteria, exclusion criteria, data collection, data analysis), animals, outcome measures to be utilized, and how the results will be analyzed. The study should be conducted in accordance with applicable regulatory requirements and local rules of conduct relating to scientific studies, which should be identified in the protocol.

FEASIBILITY

Provide adequate proof that the investigative team is appropriately equipped and has expertise in the area of study to merit funding and that the project will be approved by local ethical committee. Potential obstacles and plans to overcome them should be identified.

REFERENCES

Number references sequentially as they are cited in the text (or tables and legends), using superscripted Arabic numerals. The following styles should be used for common types of references:

Article in a journal

1. Lamont LA, Bulmer BJ, Sisson DD, et al. Doppler echocardiographic effects of medetomidine on dynamic left ventricular outflow tract obstruction in cats. J Am Vet Med Assoc 2002;221:1276–1281.

Book chapter

2. Muir P, Johnson KA, Manley PA. Fractures of the pelvis. In: Birchard SJ, Sherding RG, eds. Saunders manual of small animal practice. 2nd ed. Philadelphia: WB Saunders Co, 2000;1126–1132.

Proceeding

3. Moore MP, Bagley RS, Harrington ML, et al. Intracranial tumors, in Proceedings. 14th Annu Meet Vet Med Forum 1996;331–334.

Electronic material

4. Animal and Plant Health Inspection Service. Bovine spongiform encephalopathy (BSE). Available at: www.aphis.usda.gov/lpa/issues/bse/bse.html. Accessed Feb 18, 2003.

COMPANION ANIMAL GRANT PROGRAM by vetoquinol

VETOQUINOL COMPANION ANIMAL GRANT PROGRAM



by vetoquinol

Vetoquinol is pleased to announce the creation of the:

VETOQUINOL MOBILITY PROGRAM CLINICAL STUDY GRANT





VETOQUINOL MOBILITY PROG RAM CLINICAL STUDY GRANT

GENERAL INFORMATION

The Vetoquinol Mobility Program (VMP) is a comprehensive method of multimodal osteoarthritis management in dogs and cats combining both pharmaceutical and non-pharmaceutical solutions in order to provide pain relief, improved quality of life and return to function.

The 3 principal components of the VMP include:

Cimalgex[®], a Cox-II specific NSAID for acute and chronic pain relief in dogs

Flexadin Advanced®, a nutritional supplement containing undenatured Type-II collagen which has been shown to reduce inflammation by a mechanism called oral tolerance



Veterinary rehabilitation therapy to both diminish pain and improve function

The VMP Clinical Study Grant Program is aimed at supporting research which will demonstrate the clinical use of one or more of the principal components of the program.

RULES

- Applicants must be a veterinarian either with or in the process of obtaining an advanced degree. Proposals that include interns, residents or graduate students must have a sponsor in a faculty position or postdoctoral career appointment at the same institute
- Proposals will be submitted using the format below and will be evaluated based upon the scientific interest of the research and the feasibility of timely completion and publication
- The maximum award available for each study is 50 000 Euros
- Maximum time for completion of the study is two years

The primary aim of the award is to publish the research in a peer-reviewed veterinary journal

Investigators will comply with all local ethical requirements

Reports of progress will be made every six months

Vetoquinol will be acknowledged in any publication





SELECTION OF AWARDS

The selection committee for 2018 is chaired by Dr. Felix Duerr, Dr. med. vet., MS, Diplomate, American and European College of Veterinary Surgeons and American College of Veterinary Sports Medicine and Rehabilitation, Associate Professor of Small Animal Sports Medicine/Rehabilitation and Orthopedics at Colorado State University.

The remainder of the Committee will be composed of Vetoquinol personnel across divisions and disciplines based on the relevance of the research proposed. Vetoquinol may use other academic consultants under confidentiality agreements to help with the review process.

Research grant(s) that centers on the clinical use of one or more of the principal components of the program can be funded for up to a total of 50 000 Euros.

Selection criteria

The objective of the Grant Program is to fund research for management of osteoarthritis which will result in publication in a peer reviewed veterinary journal. Research Study proposals will be evaluated based upon the scientific interest of the research and the feasibility of timely completion and publication.

Intellectual property

It is expressly understood and agreed by the Candidates and particularly the Winner(s) that any patentable results of the Research Study will be solely owned by VETOQUINOL which shall alone decide to file patent application based on said results. In the event that the filing of a patent application is being contemplated by VETOQUINOL any publication or communication related to the results shall be deferred upon VETOQUINOL's mere request, which deferral shall last until the application is published.

BUDGET

A budget should be included with divisions by major categories of expense if possible (e.g. animal care, laboratory assays, purchase of study drug...). Itemized budgets will be required if the project is selected for funding. The maximum budget amount is 50,000 Euros. Residual funds will be required to be returned at the end of (2) years. The VMP grant will NOT pay for full-time faculty salaries, the purchase of laboratory equipment, or overhead fees.

PROPOSED TIMELINE

The timeline should be included with appropriate major milestones.

QUESTIONS AND PRINCIPAL CONTACT

Questions and additional information requests can be submitted to your local Vetoquinol technical advisor.

HOW TO SUBMIT?

To submit your grant, please contact your local Vetoquinol technical advisor. Deadline for submission: 2018, October 1st Results of grant allocation: 2018, December





